Cuál es el precio por Clover Biopharmaceuticals, Ltd. (2197)

Precio por Clover Biopharmaceuticals, Ltd. (2197) es de$0.25841098

Cuál es la capitalización de mercado por Clover Biopharmaceuticals, Ltd. (2197)

Capitalización de mercado por Clover Biopharmaceuticals, Ltd. (2197) es $335.38M

Clover Biopharmaceuticals, Ltd. (2197) Acciones en Circulación

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.

Año	Acciones en circulación	Cambiar
Not enough data for the provided dates.

Año

Acciones en circulación

Cambiar

Not enough data for the provided dates.

Empresa	Acciones en circulación	Diferencia	País
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Moderna, Inc. MRNA.US	396.00M	-	US
CSL Limited CSL.AX	478.91M	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Acciones en circulación

Diferencia

País